Literature DB >> 69273

Clonidine-induced locomotor hyperactivity in rats. The role of central postsynaptic alpha-adrenoceptors.

I Zebrowska-Lupina, E Przegalinski, M Sloniec, Z Kleinrok.   

Abstract

The alpha-adrenergic agonist, clonidine, causes sedation in normal rats. The present study demonstrates that clonidine evokes strong locomotor stimulation in rats pretreated with 6-hydroxydopamine plus reserpine. Similar, but less intensive hyperactivity is observed in rats given clonidine after combined pretreatment with 6-hydroxydopamine plus p-chlorophenylalanine plus alpha-methyl-p-tyrosine, or with reserpine plus low doses of yohimbine. The aplha-adrenolytic drugs, phenoxybenzamine, phentolamine and aceperone, as well as high doses of yohimbine, antagonise the clonidine-induced locomotor stimulation; in contrast, the dopamine receptor blocking agents, pimozide and spiroperiodol, exert no antagonistic effect. The results indicate that in the brain of normal animals, clonidine predominantly activates presynaptic alpha-adrenoceptors on noradrenergic neurones and thereby induces sedation. After destruction of the noradrenergic fibres by 6-hydroxydopamine plus reserpine, activation of postsynaptic alpha-adrenoceptors prevails so that hyperactivity results.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 69273     DOI: 10.1007/BF00509265

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  34 in total

1.  Potentiation of amphetamine-induced hyperactivity by acute but not by chronic para-chlorophenylalanine treatment in the rat.

Authors:  E Cannon; R J Wyatt; J C Gillin
Journal:  Life Sci       Date:  1976-04-01       Impact factor: 5.037

2.  The demonstration of a change in adrenergic receptor sensitivity in the central nervous system of mice after withdrawal from long-term treatment with haloperidol.

Authors:  R Dunstan; D M Jackson
Journal:  Psychopharmacology (Berl)       Date:  1976-07-09       Impact factor: 4.530

3.  Involvement of alpha-receptors in clonidine-induced inhibition of transmitter release from central monoamine neurones.

Authors:  K Starke; H Montel
Journal:  Neuropharmacology       Date:  1973-11       Impact factor: 5.250

4.  Sedative effects of alpha-sympathomimetic drugs and their antagonism by adrenergic and cholinergic blocking drugs.

Authors:  B Delbarre; H Schmitt
Journal:  Eur J Pharmacol       Date:  1971       Impact factor: 4.432

5.  Serotonergic inhibition of catecholamine-induced behavioral arousal.

Authors:  P D Mabry; B A Campbell
Journal:  Brain Res       Date:  1973-01-30       Impact factor: 3.252

6.  Dopamine and noradrenaline receptor stimulation: reversal of reserpine-induced suppression of motor activity.

Authors:  N E Andén; U Strömbom; T H Svensson
Journal:  Psychopharmacologia       Date:  1973

7.  On the mode of action of apomorphine.

Authors:  B Costall; R J Naylor
Journal:  Eur J Pharmacol       Date:  1973-03       Impact factor: 4.432

8.  A further attempt to characterize sedative receptors activated by clonidine in chickens and mice.

Authors:  B Delbarre; H Schmitt
Journal:  Eur J Pharmacol       Date:  1973-06       Impact factor: 4.432

9.  Evidence for a central alpha-sympathomimetic action of clonidine in the rat.

Authors:  L Finch; R E Buckingham; R A Moore; T J Bucher
Journal:  J Pharm Pharmacol       Date:  1975-03       Impact factor: 3.765

10.  Catecholamine receptor agonists: effects on motor activity and rate of tyrosine hydroxylation in mouse brain.

Authors:  U Strömbom
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1976       Impact factor: 3.000

View more
  24 in total

1.  Involvement of presynaptic alpha-adrenoceptors in the cardiovascular and sedative effects of FLA-136.

Authors:  P B Timmermans; E Lam; P A van Zwieten
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1979-03       Impact factor: 3.000

2.  Depression of exploratory activity by clonidine in rats as a model for the detection of relative pre- and postsynaptic central noradrenergic receptor selectivity of alpha-adrenolytic drugs.

Authors:  A Delini-Stula; P Baumann; O Büch
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1979-06       Impact factor: 3.000

3.  Naloxone-precipitated withdrawal reveals sensitization to neurotransmitters in morphine tolerant/dependent rats.

Authors:  R Schulz; A Herz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1977-08       Impact factor: 3.000

4.  A study of the possible influence of central 5-HT function on clonidine-induced hypoactivity responses in mice.

Authors:  D J Heal; J Philpot
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

5.  Modulation of motor activity by alpha 1- and alpha 2-adrenoceptor stimulation in mice.

Authors:  L Pichler; W Kobinger
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1981-09       Impact factor: 3.000

6.  Effects of alpha 2-agonists on morphine withdrawal behaviour: potentiation of jumping mediated by alpha 2-receptors.

Authors:  J W van der Laan
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-05       Impact factor: 3.000

7.  Inhibitory alpha 2-adrenergic mechanism regulating gastric secretion in pylorus-ligated rats.

Authors:  T Nakadate; T Nakaki; T Muraki; R Kato
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1982-08       Impact factor: 3.000

8.  Clonidine-induced sedation in rats: evidence for mediation by postsynaptic alpha 2-adrenoreceptors.

Authors:  C Spyraki; H C Fibiger
Journal:  J Neural Transm       Date:  1982       Impact factor: 3.575

9.  Spinal modulation of acoustic startle: opposite effects of clonidine and d-amphetamine.

Authors:  M Davis; D I Astrachan
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

10.  Effects of thyroid status on presynaptic alpha 2-adrenoceptor function and beta-adrenoceptor binding in the rat brain.

Authors:  C K Atterwill; S J Bunn; D J Atkinson; S L Smith; D J Heal
Journal:  J Neural Transm       Date:  1984       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.